Multimodal Theragnostic Anticancer Complexes of Rhenium to Circumvent Platinum Resistance in Relapsed Ovarian Cancer
Abstract
Novel rhenium-based anticancer agents were explored as alternatives to the platinum drugs for the treatment of ovarian cancer. Over the course of this reporting period, we discovered that this class of compounds is highly effective against cisplatin-resistant ovarian cancer cells, suggesting that these agents might be valuable for use in relapsed ovarian cancer. The mechanism of action of these compounds was also investigated, revealing that they induce via a non-apoptotic pathways. Furthermore, the intracellular localization, determined via confocal fluorescence microscopy, indicates that these compounds accumulate in the lysosome and endosomes. Lastly, in vivo tumor xenograft studies demonstrate that this class of compounds effectively inhibits tumor growth with minimal toxic side effects.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2018
- Accession Number
- AD1055185
Entities
People
- Justin J. Wilson
Organizations
- Cornell University